Smith D S, Carvalhal G F, Mager D E, Bullock A D, Catalona W J
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Urol. 1998 Nov;160(5):1734-8.
We evaluated differences in the prostate cancer detection rate among black and white men with serum prostate specific antigen (PSA) levels between 2.6 and 4.0 ng./ml., and benign findings on digital rectal examination.
From May 1995 through June 1997 we screened 14,209 white and 1,004 black men 50 years old or older with serum PSA and rectal examinations at 6-month intervals. If PSA was greater than 2.5 ng./ml. or the rectal examination was suspicious for cancer, we recommended an ultrasound guided sextant biopsy of the prostate. We compared differences in clinical characteristics, compliance with the recommendation for biopsy, cancer detection rate, and stage and grade of tumors detected for 924 white and 57 black men.
Black men were younger (60 versus 63 years old, p = 0.005) and presented with slightly higher PSA levels (3.3 versus 3.1 ng./ml., p = 0.03) than white men. Overall cancer detection rate was 27% (106 of 391 patients), with cancer detection 2-fold higher among black (13 of 29, 45%) than among white (93 of 362, 26%) men (p = 0.03, odds ratio 2.4, 95% confidence interval 1.1 to 5.1). Controlling for age, total PSA, PSA density, percent free PSA and number of prior screening visits, race remained a significant predictor of cancer (adjusted odds ratio 3.4, confidence interval 1.4 to 8.4). We found trends for worse pathological stage and grade among black men but these differences did not reach statistical significance.
Black race was an independent predictor of prostate cancer even at lower PSA cutoffs (2.6 to 4.0 ng./ml.). Although the positive predictive value for cancer detection was relatively high in black men, long-term outcomes studies are necessary to determine whether the use of lower PSA cutoffs would result in favorable shifts in cancer stage and grade, and a reduction in racial differences in prostate cancer mortality rates.
我们评估了血清前列腺特异性抗原(PSA)水平在2.6至4.0 ng/ml之间且直肠指检结果为良性的黑人和白人男性中前列腺癌检出率的差异。
从1995年5月至1997年6月,我们对14209名50岁及以上的白人男性和1004名黑人男性进行了筛查,每隔6个月检测血清PSA并进行直肠检查。如果PSA大于2.5 ng/ml或直肠指检怀疑有癌症,我们建议进行超声引导下的前列腺六分区活检。我们比较了924名白人男性和57名黑人男性在临床特征、活检建议的依从性、癌症检出率以及所检出肿瘤的分期和分级方面的差异。
黑人男性比白人男性更年轻(60岁对63岁,p = 0.005),PSA水平略高(3.3 ng/ml对3.1 ng/ml,p = 0.03)。总体癌症检出率为27%(391例患者中的106例),黑人男性的癌症检出率(29例中的13例,45%)是白人男性(362例中的93例,26%)的2倍(p = 0.03,优势比2.4,95%置信区间1.1至5.1)。在控制年龄、总PSA、PSA密度、游离PSA百分比和既往筛查次数后,种族仍然是癌症的显著预测因素(调整后的优势比3.4,置信区间1.4至8.4)。我们发现黑人男性的病理分期和分级有变差的趋势,但这些差异未达到统计学显著性。
即使在较低的PSA临界值(2.6至4.0 ng/ml)下,黑人种族也是前列腺癌的独立预测因素。虽然黑人男性癌症检测的阳性预测值相对较高,但需要进行长期结果研究以确定使用较低的PSA临界值是否会导致癌症分期和分级的有利变化,以及前列腺癌死亡率种族差异的减少。